Asset Details
Do you wish to reserve the book?
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
Do you wish to request the book?
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
2002
Overview
More active agents are needed in the treatment of metastatic non-small cell lung cancer. Pyrazoloacridine (PZA) is a 9-methoxy acridine compound containing a reducible 5-nitro substituent. Although the mechanism of action of PZA is unknown, the acridine compounds are known to cause cytotoxicity by interaction with DNA and RNA.
Eighteen patients with metastatic non-small cell lung carcinoma were treated with pyrazoloacridine. Pyrazoloacridine was administered as a three-hour infusion at 750 mg/M2 every 21 days.
There were no objective responses. One patient maintained stable disease for 20 months. Median survival was 4.8 months. The primary toxicity was granulocytopenia with 5 patients experiencing severe infections.
Pyrazoloacridine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung when given at this dose and schedule.
Publisher
Springer Nature B.V
Subject
Acridines - administration & dosage
/ Aged
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Hypoxia
/ Lung Neoplasms - drug therapy
/ Male
/ Pyrazoles - administration & dosage
/ Toxicity
